The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Awareness and Indications of 5-α-Reductase Inhibitors for Benign Prostatic Hyperplasia in the Primary Care Setting

Authors: Daniel S. Alicea, MS, Mustufa Babar, MD, Justin Loloi, MD, Jainam Shah, BS, Umair Azhar, MD, Kevin Labagnara, MD, Azizou Salami, BS, Kevin Tang, BS, Juan Robles, MD, Pedro Maria, DO

Abstract

Objective: The objective of the study was to investigate primary care physicians’ (PCPs’) level of awareness and indications for urology referral in patients treated with 5-α-reductase inhibitors (5-ARIs).

Methods: An anonymous 14-question survey was e-mailed to PCPs in the specialties of Family Medicine and Internal Medicine at an academic institution. Questions focused on residency graduation year, patient volume, medical practice characteristics, knowledge of 5-ARIs and their effects on prostate-specific antigen (PSA) kinetics, role of 5-ARIs in prostate cancer (PC) prevention, and indications for prostate biopsy referral.

Results: In total, 221 PCPs were e-mailed, 85 of whom responded (38.5% response rate). Approximately 39% of the PCPs surveyed were not aware of the suppressive effects of 5-ARIs on PSA, 63.5% were not sure or incorrectly answered when asked about calculating the corrected PSA of a patient who is taking 5-ARIs, 77.6% were not sure or would not refer for a prostate biopsy a patient who is taking 5-ARIs but has an elevated corrected PSA that needs to be calculated, 63.5% were not sure or believed that 5-ARIs may decrease the risk of high-grade PC, and 49.4% were not sure or believed that 5-ARIs are approved for the prevention of PC. There were no differences in responses between PCPs who were Family Medicine physicians and internists (P > 0.05 for all).

Conclusions: There is a general lack of awareness among PCPs about 5-ARIs and indications for biopsy referral in patients taking 5-ARIs. An educational opportunity exists to optimize usage of 5-ARIs and avoid delaying PC detection.
Posted in: Prostate Disorders3

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Pettaway CA, Lamerato LE, Eaddy MT, et al. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int 2011;108:1302–1308.
 
2. Chislett B, Chen D, Perera ML, et al. 5-Alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl Urol 2023;12:487–496.
 
3. Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol 2018;5:28–32.
 
4. Sarkar RR, Parsons JK, Bryant AK, et al. Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med 2019;179: 812–819.
 
5. Busato WFSJ. Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment. Int Braz J Urol 2020;46:456–458.
 
6. Choi YH, Cho SY, Cho IR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride. Korean J Urol 2010;51:704–708.
 
7. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alphareductase inhibitor dutasteride. J Urol 2006;175:1657–1662.
 
8. Thompson IM Jr, Tangen CM, Kramer B. 5α-Reductase inhibitor use in patients with prostate cancer. JAMA Intern Med 2019;179:1440.
 
9. Yafi FA, Aprikian AG, Tanguay S, et al. Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians. BJU Int 2011;108:1269–1273.
 
10. Loloi J, Wei M, Babar M, et al. Rates of false-negative screening in prostate specific antigen secondary to 5-alpha reductase inhibitor usage: a quality-improvement initiative. Int Braz J Urol 2022;48:688–695.
 
11. US Preventive Services Task Force ;Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319: 1901–1913.
   
13. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol 2023;210:45–53.
 
14. American Cancer Society. American Cancer Society recommendations for prostate cancer early detection. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html. Accessed January 18, 2025.
 
15. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761–769.
 
16. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005; 293:1223–1238.